Clinical Trial Update: Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 trial of nebulised RESP30X nitric oxide formulations in non-Cystic Fibrosis Bronchiectasis patients with Pseudomonas aeruginosa; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• Nebulised RESP30X Nitric Oxide Formulations

Snippet

Sponsor: Thirty Respiratory Limited | Conditions: Non-Cystic Fibrosis Bronchiectasis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING